A Randomized, Double-Blind, Controlled Study Of Exemestane (Aromasin) vs Anastrozole (Arimidex) As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer.

Trial Profile

A Randomized, Double-Blind, Controlled Study Of Exemestane (Aromasin) vs Anastrozole (Arimidex) As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2013

At a glance

  • Drugs Exemestane (Primary) ; Anastrozole
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 01 Jun 2013 Primary endpoint 'Time-to-disease-progression' has not been met.
    • 10 Dec 2011 Results presented at the 34th Annual San Antonio Breast Cancer Symposium.
    • 10 Mar 2011 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top